摘要
目的研究分析重组人血管内皮抑制素对非小细胞肺癌治疗效果及对患者P糖蛋白(P-gp)表达的影响。方法采用回顾性研究方法将2012年5月至2015年9月在山东大学齐鲁医院肿瘤科治疗78例非小细胞癌患者根据其治疗方法分为对照组和观察组各39例。对照组患者采取铂类+吉西他滨治疗,观察组则联合应用重组人血管内皮抑制素治疗。比较分析2组患者治疗后6个月临床疗效,P糖蛋白阳性表达,复发和不良反应情况以及1、3、5年内的生存率。结果观察组治疗总有效率(66.7%)明显高于对照组(48.7%),差异有统计学意义(P<0.05)。治疗后观察组P-gp阳性率(38.5%)明显低于对照组(59.0%),差异有统计学意义(P<0.05)。观察组复发率(20.5%)也明显低于对照组(35.9%),差异有统计学意义(P<0.05)。治疗后6个月,2组患者骨髓抑制、肝肾损害、肠道反应、白细胞下降以及心电图改变等毒副作用发生率比较,差异均无统计学意义(P>0.05)。观察组患者治疗后1年内生存率(100.0%)与对照组(97.4%)比较,差异无统计学意义(P>0.05),观察组治疗后3年及治疗后5年生存率(94.9%,79.5%)均明显高于对照组(82.1%,58.9%),差异有统计学意义(P<0.05)。结论重组人血管内皮抑制素对非小细胞肺癌患者进行治疗可明显延长患者生存期,降低P-gp阳性率,疗效确切。
Objective To study and analyze the effect of recombinant human endostatin on the treatment of non-small cell lung cancer(NSCLC)and its effect on P glycoprotein(P-gp)expression in patients.Methods Using retrospective research methods,78 patients with non-small cell carcinoma treated in the Department of Oncology,Qilu Hospital of Shandong University from May 2012 to September 2015 were divided into control group and observation group with 39 cases each,and control group patients.Platinum+gemcitabine was used for treatment,and the observation group was combined with recombinant human endostatin treatment.The clinical efficacy of the two groups of patients 6 months after treatment,the positive expression of P glycoprotein,the recurrence and side effects,and the survival rate within 1,3,and 5 years were compared and analyzed.Results The total effective rate of treatment in the observation group(66.7%)was significantly higher than that of the control group(48.7%),and the difference was significant(P<0.05);after treatment,the positive rate of P-gp in the observation group(38.5%)was significantly lower than that of the control group(59.0%),the difference is significant(P<0.05),the observation group's recurrence rate(20.5%)was also significantly lower than the control group(35.9%),the difference was significant(P<0.05);patients in the observation group survived within 1 year after treatment.Compared with the control group(97.4%),the difference was not significant(P>0.05).The survival rates(94.9%,79.5%)of the observation group were significantly higher than those of the control group at 3 years and 5 years after treatment(82.1%,58.9%),the differences were significant(P<0.05);after treatment,there was no significant difference in the incidence of side effects such as bone marrow suppression,liver and kidney damage,intestinal reaction,leukopenia,and electrocardiogram changes between the two groups(P>0.05).Conclusion Recombinant human endostatin can significantly prolong the survival time of patients with non-small cell lung
作者
刘方
刘凤英
王哲海
LIU Fang;LIU Feng-ying;WANG Zhe-hai(Shandong First Medical University,Jinan Shandong 251400,China;Department of Oncology,Qilu Hospital of Shandong University,Jinan Shandong 250012,China;Department of Oncology,Shandong Cancer Hospital,Jinan Shandong 250000,China)
出处
《临床和实验医学杂志》
2021年第2期166-169,共4页
Journal of Clinical and Experimental Medicine
基金
山东省教育厅科研课题(编号:3035b2078)。
